Featured Research

from universities, journals, and other organizations

T-cell research sheds light on why HIV can persist despite treatment

Date:
January 14, 2014
Source:
University of Delaware
Summary:
Research by an international team provides evidence that a particular T-cell type may help researchers better understand why HIV can persist despite treatment.

Ryan Zurakowski (left), shown with doctoral student Fabian Cardozo, is co-author of a paper appearing in Nature Medicine highlighting the role of T-cells in HIV.
Credit: University of Delaware

Ryan Zurakowski, assistant professor of electrical and computer engineering at the University of Delaware, is co-author of a paper appearing in Nature Medicine on Jan. 12 highlighting the role of T-cells in HIV.

The paper, titled "HIV-1 Persistence in CD4+ T-Cells with Stem Cell-Like Properties," provides evidence that a particular T-cell type may help researchers better understand why HIV can persist despite treatment.

Zurakowski's co-authors include Mathias Lichterfeld, the paper's lead author, and researchers from Massachusetts General Hospital (MGH); Ragon Institute of MGH, the Massachusetts Institute of Technology and Harvard University; the First Affiliated Hospital of China Medical University; Brigham and Women's Hospital; and Howard Hughes Medical Institute.

Zurakowski explained that HIV treatments do not kill infected cells. Instead, they stop the infection of new cells, and rely on the virus itself to kill the infected cells. Unfortunately, some cells infected by the virus -- memory T-cells -- are not killed by the virus.

T-cells are a type of lymphocyte, or white blood cell, produced by the thymus gland, that actively participates in the body's immune response. "Memory" T-cells can live for years, or even decades, providing life-long immunity to previously encountered diseases. They can form "quiescent" infections, which last for years, and cause HIV to rebound whenever a patient stops treatment.

During a decade-long study, the researchers discovered that not all memory T-cells are alike. A subgroup of memory T-cells, called "Stem-Cell Memory T-cells" (Tscm), are different, particularly in their ability to produce daughter cells.

The researchers were able to show that the HIV-infected Tscm cells in patients on HIV therapy decayed more slowly than any other type of T-cell. As a result, after 10 years of therapy, the Tscm cells represented 24 percent of the total HIV infected cell population, despite being only 1 percent of the total T-cell population.

This finding is significant, Zurakowski said, because it demonstrates that Tscm cells are the slowest-decaying portion of the HIV reservoir.

"Over time this particular cell type plays an increasingly significant role in sustaining HIV infection in patients that have remained on therapy," he said.

Zurakowski credits the finding to the diligence of Lichterfeld and the researchers at the Ragon Institute in carefully following the same HIV patients for a decade.

"Because the researchers have followed the same patients over a decade, we have created a high fidelity data set that would not otherwise have been possible," he said.

Drugs currently being developed for cancer therapy that target stem-cell metabolic pathways may be able to target this cell type as well, due to the "stem-cell like" nature of the Tscm cells, he continued.

A better understanding of how the HIV virus leverages a cell's stem cell-like properties of cellular immune memory to stay alive could lead to improved clinical strategies for HIV treatment.

"If we can find a way to selectively eliminate the HIV-infected Tscm cells, it will be a major step in developing a true 'cure' for HIV infection," concluded Zurakowski.


Story Source:

The above story is based on materials provided by University of Delaware. Note: Materials may be edited for content and length.


Journal Reference:

  1. Maria J Buzon, Hong Sun, Chun Li, Amy Shaw, Katherine Seiss, Zhengyu Ouyang, Enrique Martin-Gayo, Jin Leng, Timothy J Henrich, Jonathan Z Li, Florencia Pereyra, Ryan Zurakowski, Bruce D Walker, Eric S Rosenberg, Xu G Yu, Mathias Lichterfeld. HIV-1 persistence in CD4 T cells with stem cell–like properties. Nature Medicine, 2014; DOI: 10.1038/nm.3445

Cite This Page:

University of Delaware. "T-cell research sheds light on why HIV can persist despite treatment." ScienceDaily. ScienceDaily, 14 January 2014. <www.sciencedaily.com/releases/2014/01/140114092140.htm>.
University of Delaware. (2014, January 14). T-cell research sheds light on why HIV can persist despite treatment. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2014/01/140114092140.htm
University of Delaware. "T-cell research sheds light on why HIV can persist despite treatment." ScienceDaily. www.sciencedaily.com/releases/2014/01/140114092140.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins